In early August, Triangle Pharmaceuticals Inc.'s stock shot up surrounding favorable interim data from a Phase III trial of the company's lead product candidate for HIV. And Thursday, the stock was up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results